Imbruvica ibrutinib: Phase Ib data

Data from the Phase Ib portion of the open-label, U.S. Phase Ib/II PCYC-1129 trial showed that once-daily Imbruvica led to no DLTs. The recommended dose for the Phase II portion is 420 mg once-daily I...